Zacks Investment Research
05 Nov 2026, 20:55 UTC · 46m ago
Envista Q3 Earnings Call Highlights '26 Guidance Raise & China Risks
Impact · against what's priced in
Envista's immediate outlook is positive due to an EPS guidance raise and a Q3 beat, but these gains are overshadowed by severe structural risks in China. The specific quantification of pricing drops for orthodontics (50%) and implants (10-15%) starting in 2027 introduces a significant long-term margin headwind.
- NVST−0.10
No priced-in read yet
- In context
While the 2026 EPS guidance raise to $1.54-$1.58 and the Q3 beat are positive, they are offset by the disclosure of severe pricing pressure in China for 2027, specifically a projected 50% drop in orthodontics pricing and a 10-15% drop in implant pricing.
Read from the article alone
